Immune Checkpoint Inhibitors
Phase 2Small molecule
Immune Checkpoint Inhibitors is one of 276 small molecule programs targeting Autoimmune Disease. It is currently in Phase 2.
10
Indications
19
Total Trials
15
Active Trials
275
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Tabrecta
NovartisPhase 3
Rozlytrek
RochePhase 3
Tepmetko
EMD SeronoPhase 3
Immune Checkpoint Inhibitors
PPeking Union Medical College Hospital
Phase 2
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Esophageal Squamous Cell Carcinoma2 trials
Immune Checkpoint Inhibitors2 trials
Immunotherapy2 trials
Autoimmune Disease1 trial
Gastric Cancer1 trial
A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06685887·34 enrolled
11 more indications
Immune-related Adverse Events1 trial
Survival1 trial
Non-Small Cell Lung Cancer1 trial
Treatment1 trial
Esophageal Carcinoma1 trial
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
Recruiting·—·Phase 1/2·NCT05937438·70 enrolled
Malignant Tumors1 trial
Solid Tumor1 trial
Melanoma1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details